Table 1.

Demographic features of study populations

Demographic featuren
Age (y), median (range) 54 (23-73) 
Sex (%)  
 Male 18 (62) 
 Female 11 (38) 
Race (%)  
 Black 8 (29) 
 White 17 (59) 
 Asian 3 (10) 
 Other 1 (3) 
Ethnicity (%)  
 Hispanic 7 (24) 
 Non-Hispanic 22 (76) 
Disease type (%)  
 B-cell lymphomas 7 (24) 
  Burkitt 1 (3) 
  DLBCL 1 (3) 
  Follicular 5 (17) 
 T-cell lymphomas 18 (62) 
  ATLL 6 (21) 
  ALCL ALK(−) 3 (10) 
  Sezary syndrome 2 (7) 
  CTCL 1 (3) 
  CD4+ T cell 1 (3) 
  Hepatosplenic T cell 1 (3) 
  Intestinal T cell 1 (3) 
  NK T cell 1 (3) 
  PTCL 1 (3) 
  SPTL-AB 1 (3) 
 Other 4 (14) 
  Blastic plasmacytoid dendritic cell neoplasm 1 (3) 
  Hodgkin lymphoma 3 (10) 
Prior therapies, median (range) 3 (1-16) 
 CHOP/RCHOP/CHOEP/EPOCH/hyper-CVAD 24 (83) 
 Experimental therapies: clinical trials 11 (38) 
 Gemcitabine based: GEM/GemiFOX/GemOX/GVD 9 (31) 
 HDAC inhibitors 9 (31) 
 Alkylator based: Benda/CTX/CVP 8 (28) 
 Platinum based: RICE/ICE/DHAP/ESHAP 7 (24) 
 Radiation 7 (24) 
 Biologics: bexarotene/ublituximab/Rituxan 7 (24) 
 Autologous stem cell transplant 6 (21) 
 MTX/SMILE 5 (17) 
 ABVD/ABV-COPP/MOPP 4 (14) 
 Brentuximab vedotin 4 (14) 
 Lenalidomide based 4 (14) 
 Phototherapy: light/PUVA 3 (10) 
 Pralatrexate 2 (7) 
 Allogeneic transplant 1 (3) 
Demographic featuren
Age (y), median (range) 54 (23-73) 
Sex (%)  
 Male 18 (62) 
 Female 11 (38) 
Race (%)  
 Black 8 (29) 
 White 17 (59) 
 Asian 3 (10) 
 Other 1 (3) 
Ethnicity (%)  
 Hispanic 7 (24) 
 Non-Hispanic 22 (76) 
Disease type (%)  
 B-cell lymphomas 7 (24) 
  Burkitt 1 (3) 
  DLBCL 1 (3) 
  Follicular 5 (17) 
 T-cell lymphomas 18 (62) 
  ATLL 6 (21) 
  ALCL ALK(−) 3 (10) 
  Sezary syndrome 2 (7) 
  CTCL 1 (3) 
  CD4+ T cell 1 (3) 
  Hepatosplenic T cell 1 (3) 
  Intestinal T cell 1 (3) 
  NK T cell 1 (3) 
  PTCL 1 (3) 
  SPTL-AB 1 (3) 
 Other 4 (14) 
  Blastic plasmacytoid dendritic cell neoplasm 1 (3) 
  Hodgkin lymphoma 3 (10) 
Prior therapies, median (range) 3 (1-16) 
 CHOP/RCHOP/CHOEP/EPOCH/hyper-CVAD 24 (83) 
 Experimental therapies: clinical trials 11 (38) 
 Gemcitabine based: GEM/GemiFOX/GemOX/GVD 9 (31) 
 HDAC inhibitors 9 (31) 
 Alkylator based: Benda/CTX/CVP 8 (28) 
 Platinum based: RICE/ICE/DHAP/ESHAP 7 (24) 
 Radiation 7 (24) 
 Biologics: bexarotene/ublituximab/Rituxan 7 (24) 
 Autologous stem cell transplant 6 (21) 
 MTX/SMILE 5 (17) 
 ABVD/ABV-COPP/MOPP 4 (14) 
 Brentuximab vedotin 4 (14) 
 Lenalidomide based 4 (14) 
 Phototherapy: light/PUVA 3 (10) 
 Pralatrexate 2 (7) 
 Allogeneic transplant 1 (3) 

ABV-COPP, adriamycin, bleomycin, vinblastin, cyclophosphamide, vincristine, procarbazine, prednisone; ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; ATLL, adult T-cell leukemia/lymphoma; CHOEP, cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CTCL, cutaneous T-cell lymphoma; CTX, cyclophosphamide; CVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone; CVP, cyclophosphamide, vincristine, prednisone; DHAP, dexamethasone, high dose cytarabine, cisplatin; DLBCL, diffuse large B-cell lymphoma; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, adriamycin; ESHAP, etoposide, solumedrol, high dose cytarabine, cisplatin; GEM, gemcitabine; GemiFOX, gemcitabine, ifosfamide, oxaliplatin; GemOX, gemcitabine, oxaliplatin; GVD, gemcitabine, vinorelbine, doxil; ICE, ifosfamide, carboplatin, etoposide; MOPP, mustargen, vincristine, procarbazine, prednisone; MTX, methotrexate; NK, natural killer; PUVA, psoralen and UV A; RCHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; RICE, rituxan, ifosfamide, carboplatin, etoposide; SPTL-AB, subpanniculitis-like T-cell lymphoma alpha/beta.

Close Modal

or Create an Account

Close Modal
Close Modal